JP2015522252A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522252A5 JP2015522252A5 JP2015509123A JP2015509123A JP2015522252A5 JP 2015522252 A5 JP2015522252 A5 JP 2015522252A5 JP 2015509123 A JP2015509123 A JP 2015509123A JP 2015509123 A JP2015509123 A JP 2015509123A JP 2015522252 A5 JP2015522252 A5 JP 2015522252A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- antigen binding
- binding protein
- cd30l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims 18
- 108091000831 antigen binding proteins Proteins 0.000 claims 18
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 claims 10
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 claims 10
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims 10
- 108091035707 Consensus sequence Proteins 0.000 claims 6
- 101000638255 Homo sapiens Tumor necrosis factor ligand superfamily member 8 Proteins 0.000 claims 3
- 102000054539 human TNFSF8 Human genes 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639637P | 2012-04-27 | 2012-04-27 | |
| US61/639,637 | 2012-04-27 | ||
| PCT/US2013/038135 WO2013163377A1 (en) | 2012-04-27 | 2013-04-25 | Human cd30 ligand antigen binding proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522252A JP2015522252A (ja) | 2015-08-06 |
| JP2015522252A5 true JP2015522252A5 (OSRAM) | 2016-06-16 |
| JP6370774B2 JP6370774B2 (ja) | 2018-08-08 |
Family
ID=48289696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509123A Active JP6370774B2 (ja) | 2012-04-27 | 2013-04-25 | ヒトｃｄ３０リガンド抗原結合性タンパク質 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9926373B2 (OSRAM) |
| EP (4) | EP3431492B1 (OSRAM) |
| JP (1) | JP6370774B2 (OSRAM) |
| KR (4) | KR102213694B1 (OSRAM) |
| CN (3) | CN104507968B (OSRAM) |
| AU (5) | AU2013251541B2 (OSRAM) |
| BR (2) | BR112014026531B1 (OSRAM) |
| CA (1) | CA2871750A1 (OSRAM) |
| CY (1) | CY1124050T1 (OSRAM) |
| DK (2) | DK2841456T3 (OSRAM) |
| ES (2) | ES2857900T3 (OSRAM) |
| HU (2) | HUE039118T2 (OSRAM) |
| IL (3) | IL307989A (OSRAM) |
| LT (1) | LT3431492T (OSRAM) |
| MX (1) | MX357327B (OSRAM) |
| PL (2) | PL2841456T3 (OSRAM) |
| PT (2) | PT2841456T (OSRAM) |
| RU (1) | RU2650800C2 (OSRAM) |
| SI (2) | SI3431492T1 (OSRAM) |
| TW (1) | TWI641618B (OSRAM) |
| WO (1) | WO2013163377A1 (OSRAM) |
| ZA (1) | ZA201407355B (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2841456T3 (en) * | 2012-04-27 | 2018-08-13 | Novo Nordisk As | HUMAN CD30 LIGAND ANTI-BINDING PROTEINS |
| US20150315566A1 (en) * | 2014-04-30 | 2015-11-05 | The Board Of Trustees Of The University Of Illinois | Method for generating high affinity, bivalent binding agents |
| US11473080B2 (en) | 2014-04-30 | 2022-10-18 | The Board Of Trustees Of The University Of Illinois | Method for generating high affinity, bivalent binding agents for sandwich assays |
| CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| JP2020521452A (ja) | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| MX2020001489A (es) * | 2017-08-10 | 2020-03-20 | Grifols Diagnostic Solutions Inc | Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano. |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| EP4296285A3 (en) | 2018-04-30 | 2024-02-28 | Cedars-Sinai Medical Center | Methods and systems for selection and treatment of patients with inflammatory diseases |
| WO2020096046A1 (ja) * | 2018-11-09 | 2020-05-14 | 国立大学法人大阪大学 | 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン |
| WO2020135426A1 (zh) * | 2018-12-24 | 2020-07-02 | 信达生物制药(苏州)有限公司 | 全人源的抗cd30单链抗体及其应用 |
| CA3141327A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Operations, Inc. | Madcam targeted immunotolerance |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| JP2024503508A (ja) | 2021-01-15 | 2024-01-25 | シージェン インコーポレイテッド | 免疫調節性抗体－薬物コンジュゲート |
| MX2023009113A (es) | 2021-02-03 | 2023-08-10 | Seagen Inc | Conjugados y compuestos inmunoestimulantes. |
| GEP20257791B (en) * | 2021-02-17 | 2025-09-10 | Dr Falk Pharma Gmbh | Anti-cd30l antibodies and uses thereof |
| WO2023215740A1 (en) | 2022-05-06 | 2023-11-09 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
| US20250340660A1 (en) * | 2022-07-25 | 2025-11-06 | Prometheus Biosciences, Inc. | Anti-cd30l antibodies, formulations therefor, and uses thereof |
| KR20250058121A (ko) | 2022-08-03 | 2025-04-29 | 씨젠 인크. | 면역자극성 항-pd-l1-약물 접합체 |
| EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
| WO2024143497A1 (ja) * | 2022-12-28 | 2024-07-04 | 国立大学法人京都大学 | Ｃｄ１５３を標的とする医薬組成物 |
| TW202513588A (zh) | 2023-09-12 | 2025-04-01 | 美商安進公司 | 抗ｃｄ３０ｌ抗體及其用途 |
| WO2025075049A1 (ja) * | 2023-10-03 | 2025-04-10 | 国立大学法人京都大学 | ヒトｃｄ１５３を標的とする抗体ならびにキメラ抗原受容体 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5462990A (en) * | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| AU2249592A (en) | 1991-06-14 | 1993-01-12 | Dnx Corporation | Production of human hemoglobin in transgenic pigs |
| DE69224906T2 (de) | 1991-07-08 | 1998-10-29 | Univ Massachusetts | Thermotropes flüssig-kristallines segment-blockcopolymer |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| ES2252732T3 (es) * | 1992-05-26 | 2006-05-16 | Immunex Corporation | Nueva citoquina que une cd30. |
| SG48760A1 (en) | 1992-07-24 | 2003-03-18 | Abgenix Inc | Generation of xenogenetic antibodies |
| EP0672141B1 (en) | 1992-10-23 | 2003-05-14 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| WO1999040187A1 (de) | 1998-02-06 | 1999-08-12 | Hinrich Abken | Nukleinsäuren zur modulation zellulärer aktivierung |
| AU770555B2 (en) | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6652854B2 (en) * | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| AU2006202590A1 (en) * | 2000-08-08 | 2006-07-06 | Immunex Corporation | Methods for treating autoimmune and inflammatory conditions using antagonists of CD30 or CD30L |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7090843B1 (en) * | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US20040038349A1 (en) * | 2001-07-27 | 2004-02-26 | Hilbert David M. | Heteromultimeric TNF ligand family members |
| JP2005021110A (ja) | 2003-07-04 | 2005-01-27 | Toyama Chem Co Ltd | Ｃｄ３０リガンドおよび／またはｃｄ３０の発現誘導剤、アポトーシス誘導剤ならびにそれらを含有する医薬組成物。 |
| JP5427027B2 (ja) * | 2006-05-03 | 2014-02-26 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド，ア・ボディー・コーポレイト | Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用 |
| US7982016B2 (en) * | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| CA2831820C (en) * | 2011-04-01 | 2021-05-25 | Universitat Stuttgart | Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof |
| DK2841456T3 (en) * | 2012-04-27 | 2018-08-13 | Novo Nordisk As | HUMAN CD30 LIGAND ANTI-BINDING PROTEINS |
-
2013
- 2013-04-25 DK DK13720714.8T patent/DK2841456T3/en active
- 2013-04-25 DK DK18169942.2T patent/DK3431492T3/da active
- 2013-04-25 EP EP18169942.2A patent/EP3431492B1/en active Active
- 2013-04-25 KR KR1020207000990A patent/KR102213694B1/ko active Active
- 2013-04-25 SI SI201331852T patent/SI3431492T1/sl unknown
- 2013-04-25 BR BR112014026531-3A patent/BR112014026531B1/pt active IP Right Grant
- 2013-04-25 SI SI201331123T patent/SI2841456T1/sl unknown
- 2013-04-25 KR KR1020147031292A patent/KR101932697B1/ko active Active
- 2013-04-25 PL PL13720714T patent/PL2841456T3/pl unknown
- 2013-04-25 EP EP20207117.1A patent/EP3929208A1/en not_active Withdrawn
- 2013-04-25 KR KR1020217003317A patent/KR102292840B1/ko active Active
- 2013-04-25 CA CA2871750A patent/CA2871750A1/en active Pending
- 2013-04-25 WO PCT/US2013/038135 patent/WO2013163377A1/en not_active Ceased
- 2013-04-25 EP EP22188601.3A patent/EP4230641A3/en active Pending
- 2013-04-25 KR KR1020187036937A patent/KR20180137614A/ko not_active Withdrawn
- 2013-04-25 RU RU2014146503A patent/RU2650800C2/ru active
- 2013-04-25 IL IL307989A patent/IL307989A/en unknown
- 2013-04-25 PT PT13720714T patent/PT2841456T/pt unknown
- 2013-04-25 CN CN201380033217.6A patent/CN104507968B/zh active Active
- 2013-04-25 US US14/396,248 patent/US9926373B2/en active Active
- 2013-04-25 CN CN201910026631.3A patent/CN110078818B/zh active Active
- 2013-04-25 PT PT181699422T patent/PT3431492T/pt unknown
- 2013-04-25 LT LTEP18169942.2T patent/LT3431492T/lt unknown
- 2013-04-25 JP JP2015509123A patent/JP6370774B2/ja active Active
- 2013-04-25 MX MX2014012800A patent/MX357327B/es active IP Right Grant
- 2013-04-25 ES ES18169942T patent/ES2857900T3/es active Active
- 2013-04-25 BR BR122021001199-0A patent/BR122021001199B1/pt active IP Right Grant
- 2013-04-25 AU AU2013251541A patent/AU2013251541B2/en active Active
- 2013-04-25 IL IL276294A patent/IL276294B2/en unknown
- 2013-04-25 HU HUE13720714A patent/HUE039118T2/hu unknown
- 2013-04-25 PL PL18169942T patent/PL3431492T3/pl unknown
- 2013-04-25 ES ES13720714.8T patent/ES2682118T3/es active Active
- 2013-04-25 EP EP13720714.8A patent/EP2841456B1/en active Active
- 2013-04-25 HU HUE18169942A patent/HUE053362T2/hu unknown
- 2013-04-25 CN CN202311208153.0A patent/CN117264057A/zh active Pending
- 2013-04-26 TW TW102114993A patent/TWI641618B/zh active
-
2014
- 2014-10-07 IL IL235036A patent/IL235036B/en active IP Right Grant
- 2014-10-09 ZA ZA2014/07355A patent/ZA201407355B/en unknown
-
2018
- 2018-02-27 US US15/907,002 patent/US20180298105A1/en not_active Abandoned
- 2018-04-18 AU AU2018202699A patent/AU2018202699A1/en not_active Abandoned
-
2020
- 2020-03-12 AU AU2020201820A patent/AU2020201820B2/en active Active
-
2021
- 2021-03-03 CY CY20211100179T patent/CY1124050T1/el unknown
- 2021-10-22 US US17/452,042 patent/US20220112295A1/en not_active Abandoned
-
2022
- 2022-08-18 AU AU2022218573A patent/AU2022218573A1/en not_active Abandoned
-
2024
- 2024-12-18 US US18/985,988 patent/US20250289898A1/en active Pending
-
2025
- 2025-08-28 AU AU2025223812A patent/AU2025223812A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522252A5 (OSRAM) | ||
| RU2014146503A (ru) | Белки, связывающие антиген - лиганд cd30 человека | |
| JP2020500538A5 (OSRAM) | ||
| JP2012504955A5 (OSRAM) | ||
| AR123305A2 (es) | Proteínas de unión a antígeno | |
| IL261585A (en) | Antigen-binding human proteins that bind beta-klotho, fgf receptors and their complexes | |
| JP2019504032A5 (OSRAM) | ||
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| JP2018521638A5 (OSRAM) | ||
| JP2011528902A5 (OSRAM) | ||
| AR086579A1 (es) | Proteinas de union a antigeno | |
| JP2015120706A5 (OSRAM) | ||
| RU2016129113A (ru) | Антитела к pd-1 собак | |
| JP2014524748A5 (OSRAM) | ||
| JP2019536806A5 (OSRAM) | ||
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| JP2018535650A5 (OSRAM) | ||
| JP2014526898A5 (OSRAM) | ||
| JP2015508762A5 (OSRAM) | ||
| JP2011514150A5 (OSRAM) | ||
| JP2008538564A5 (OSRAM) | ||
| JP2013520996A5 (OSRAM) | ||
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| PE20170687A1 (es) | Proteinas de enlace a cd127 | |
| AR081556A1 (es) | Proteinas de union al antigeno humanizadas |